@article{ea6e3d3cdc784de6bce1c46b4bd7fb09,
title = "Acute lymphoblastic leukemia, version 1.2019 featured updates to the NCCN guidelines",
abstract = "Survival outcomes for older adults with acute lymphoblastic leukemia (ALL) are poor and optimal management is challenging due to higher-risk leukemia genetics, comorbidities, and lower tolerance to intensive therapy. A critical understanding of these factors guides the selection of frontline therapies and subsequent treatment strategies. In addition, there have been recent developments in minimal/measurable residual disease (MRD) testing and blinatumomab use in the context of MRD-positive disease after therapy. These NCCN Guidelines Insights discuss recent updates to the NCCN Guidelines for ALL regarding upfront therapy in older adults and MRD monitoring/testing in response to ALL treatment.",
author = "Brown, {Patrick A.} and Matthew Wieduwilt and Aaron Logan and DeAngelo, {Daniel J.} and Wang, {Eunice S.} and Amir Fathi and Cassaday, {Ryan D.} and Mark Litzow and Anjali Advani and Patricia Aoun and Bhavana Bhatnagar and Boyer, {Michael W.} and Teresa Bryan and Burke, {Patrick W.} and Coccia, {Peter F.} and Coutre, {Steven E.} and Nitin Jain and Suzanne Kirby and Arthur Liu and Stephanie Massaro and Mattison, {Ryan J.} and Olalekan Oluwole and Nikolaos Papadantonakis and Jae Park and Rubnitz, {Jeffrey E.} and Uy, {Geoffrey L.} and Gregory, {Kristina M.} and Ndiya Ogba and Bijal Shah",
note = "Funding Information: This activity is supported by educational grants from AstraZeneca, Celgene Corporation, Clovis Oncology, Eisai, Genentech, Genomic Health, Inc., Novartis, Taiho Oncology, Inc., and TESARO. This activity is supported by an independent educational grant from AbbVie. This activity is supported by educational funding provided by Amgen. This activity is supported by an unrestricted educational grant from Gilead Sciences, Medical Affairs. Publisher Copyright: {\textcopyright} National Comprehensive Cancer Network, Inc. 2019.",
year = "2019",
doi = "10.6004/jnccn.2019.0024",
language = "English",
volume = "17",
pages = "414--423",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
number = "5",
}